Iressa Expanded Access Program (EAP)

An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00034879

Enrollment

Unknown

Registered

2002-05-03

Start date

2000-08-31

Completion date

2003-10-31

Last updated

2013-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Metastases, Neoplasm, Non-small-cell Lung

Keywords

Locally advanced and/or metastatic non-operable, non-small cell lung cancer (stage III or IV), patients who have failed standard therapy.

Brief summary

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.

Interventions

DRUGZD1839 (Gefitinib)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For inclusion in this trial, patients must fulfill all of the following criteria: * previous documented histologically or cytologically confirmed non-small cell lung cancer; * locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV)patients who have received at least one course of standard systemic chemotherapy or radiation therapy or are ineligible for chemotherapy or radiotherapy or are ineligible or not a candidate for enrollment on another ZD1839 trial or who, in the Investigator's opinion, are not medically suitable for chemotherapy. * age 18 years or older; * written informed consent to participate in the trial.

Exclusion criteria

Any of the following will exclude a patient from entering the trial: * receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer medication or any other investigational agent. \* Non-cytotoxic or hormonal therapies for the adjuvant treatment of cancer or for previously treated cancers may be allowed per AstraZeneca permission; * patients eligible for or previously enrolled on a ZD1839 blinded clinical trial protocol. Patients eligible for or previously enrolled on an open-label or unblinded ZD1839 clinical trial may be considered for acceptance into the Expanded Access Program with AstraZeneca permission; * having other active malignancies; * incomplete healing from previous oncologic or other major surgery; * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial; * pregnancy or breast feeding (women of child-bearing potential).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026